Stephen P. Kahanic

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 868 citations · Full text

Hematological Malignancy, Dexamethasone Versus Lenalidomide, Oncology +9

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G.M. Durie, Antje Hoering, Rachael Sexton et al. · Blood Cancer Journal · 2020 · 246 citations · Full text

Tetracycline to prevent epidermal growth factor receptor inhibitor‐induced skin rashes

Aminah Jatoi, Kendrith M. Rowland, Jeff A. Sloan et al. · Cancer · 2008 · 172 citations · Full text

Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Patients With Chemotherapy-Associated Anemia

David P. Steensma, Jeff A. Sloan, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2010 · 119 citations · Full text

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC

Stephanie L. Hines, Betty A. Mincey, Todor Dentchev et al. · Breast Cancer Research and Treatment · 2009 · 85 citations · Full text

Bone Disease, Zoledronic Acid, Bone Loss +10